New approaches to radio- and chemosensitization using proton pump inhibitors through the lens of tumor cell microenvironment patterns

Anaphylaxis to proton pump inhibitors.

Proton pump inhibitors (PPI) are widely used for the treatment of peptic ulcer, but cases of anaphylactic reactions have rarely been described. We present a patient who experienced an episode of urticaria 30 minutes after oral intake of an omeprazole capsule. Skin prick tests to omeprazole, pantoprazole and lansoprazole were positive. Challenge test with lansoprazole was carried out and within ...

Proton Pump Inhibitors: Omeprazole

Oral Proton Pump Inhibitors

There is currently a lack of evidence to suggest superior clinical efficacy of one oral proton pump inhibitor over any other. Proton pump inhibitors display similar doseresponse relationships with similar potencies and efficacies at the equivalent dose. The decision to select one proton pump inhibitor over another is likely to be based on the agents’ licensed indication, patient tolerability an...

Intravenous proton pump inhibitors.

Intravenous (IV) administration of a proton pump inhibitor (PPI) is a faster way to achieve gastric acid suppression than oral administration of the same agent. Peak suppression after IV administration occurs within hours, compared with several days later after oral administration. Thus the IV route of administration offers a faster onset of gastric suppression, achievement of intragastric pH c...

The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors

We have recently reported that lowering the pH to values that are frequently detected in tumors causes reversible anergy in both human and mouse CD8+ T lymphocytes in vitro. The same occurs in vivo, in the tumor microenvironment and the administration of proton pump inhibitors, which buffer tumor acidity, can revert T-cell anergy and increase the efficacy of immunotherapy.